Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Khk4827 140mg Sc

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (1)
Phase 4 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02052609Phase 3Completed

A Phase 3 Clinical Study of KHK 4827

NCT04183881Phase 4Completed

A Phase 4 Clinical Study of Brodalumab

Showing all 2 trials

Research Network

Common Treatments

  • Khk4827 140mg Sc1
  • Brodalumab1
  • Khk4827 210mg Sc1

Active Sponsors

  • Kyowa Kirin Co., Ltd.2

Related Conditions

  • Psoriatic Erythroderma2
  • Psoriatic Arthritis2
  • Psoriasis Vulgaris2

Activity Timeline